Logo image of ADCT

ADC THERAPEUTICS SA (ADCT) Stock Fundamental Analysis

NYSE:ADCT - New York Stock Exchange, Inc. - CH0499880968 - Common Stock - Currency: USD

3.215  -0.14 (-4.03%)

Fundamental Rating

2

Taking everything into account, ADCT scores 2 out of 10 in our fundamental rating. ADCT was compared to 558 industry peers in the Biotechnology industry. ADCT may be in some trouble as it scores bad on both profitability and health. ADCT is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ADCT had negative earnings in the past year.
ADCT had a negative operating cash flow in the past year.
In the past 5 years ADCT always reported negative net income.
ADCT had a negative operating cash flow in each of the past 5 years.
ADCT Yearly Net Income VS EBIT VS OCF VS FCFADCT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

The Return On Assets of ADCT (-54.98%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -54.98%
ROE N/A
ROIC N/A
ROA(3y)-48.71%
ROA(5y)-46.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ADCT Yearly ROA, ROE, ROICADCT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100

1.3 Margins

ADCT has a better Gross Margin (92.75%) than 93.91% of its industry peers.
In the last couple of years the Gross Margin of ADCT has declined.
The Profit Margin and Operating Margin are not available for ADCT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 92.75%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.51%
GM growth 5YN/A
ADCT Yearly Profit, Operating, Gross MarginsADCT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

2

2. Health

2.1 Basic Checks

ADCT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ADCT has more shares outstanding
Compared to 5 years ago, ADCT has more shares outstanding
The debt/assets ratio for ADCT is higher compared to a year ago.
ADCT Yearly Shares OutstandingADCT Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
ADCT Yearly Total Debt VS Total AssetsADCT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

Based on the Altman-Z score of -7.84, we must say that ADCT is in the distress zone and has some risk of bankruptcy.
ADCT has a Altman-Z score of -7.84. This is in the lower half of the industry: ADCT underperforms 68.82% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -7.84
ROIC/WACCN/A
WACC5.44%
ADCT Yearly LT Debt VS Equity VS FCFADCT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 4.46 indicates that ADCT has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 4.46, ADCT is in line with its industry, outperforming 49.28% of the companies in the same industry.
ADCT has a Quick Ratio of 4.16. This indicates that ADCT is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 4.16, ADCT is in line with its industry, outperforming 49.28% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.46
Quick Ratio 4.16
ADCT Yearly Current Assets VS Current LiabilitesADCT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

6

3. Growth

3.1 Past

ADCT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 47.27%, which is quite impressive.
The Revenue for ADCT has decreased by -37.54% in the past year. This is quite bad
The Revenue has been growing by 98.48% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)47.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%35.71%
Revenue 1Y (TTM)-37.54%
Revenue growth 3Y27.85%
Revenue growth 5Y98.48%
Sales Q2Q%27.59%

3.2 Future

Based on estimates for the next years, ADCT will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.37% on average per year.
The Revenue is expected to grow by 33.94% on average over the next years. This is a very strong growth
EPS Next Y22.36%
EPS Next 2Y9.77%
EPS Next 3Y12.37%
EPS Next 5YN/A
Revenue Next Year6.59%
Revenue Next 2Y8.42%
Revenue Next 3Y25.43%
Revenue Next 5Y33.94%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ADCT Yearly Revenue VS EstimatesADCT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M 400M
ADCT Yearly EPS VS EstimatesADCT Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ADCT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ADCT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ADCT Price Earnings VS Forward Price EarningsADCT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ADCT Per share dataADCT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as ADCT's earnings are expected to grow with 12.37% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.77%
EPS Next 3Y12.37%

More info and screens

0

5. Dividend

5.1 Amount

ADCT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ADC THERAPEUTICS SA

NYSE:ADCT (7/15/2025, 3:30:00 PM)

3.215

-0.14 (-4.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-14 2025-05-14/bmo
Earnings (Next)08-04 2025-08-04/amc
Inst Owners53.64%
Inst Owner Change0%
Ins Owners6.6%
Ins Owner Change40.51%
Market Cap318.86M
Analysts86.67
Price Target8.41 (161.59%)
Short Float %6.84%
Short Ratio6.04
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.71%
Min EPS beat(2)12.49%
Max EPS beat(2)30.94%
EPS beat(4)3
Avg EPS beat(4)14.44%
Min EPS beat(4)-4.24%
Max EPS beat(4)30.94%
EPS beat(8)5
Avg EPS beat(8)-6.98%
EPS beat(12)6
Avg EPS beat(12)-11.45%
EPS beat(16)9
Avg EPS beat(16)-1.8%
Revenue beat(2)1
Avg Revenue beat(2)7.37%
Min Revenue beat(2)-12.78%
Max Revenue beat(2)27.51%
Revenue beat(4)1
Avg Revenue beat(4)0.9%
Min Revenue beat(4)-12.78%
Max Revenue beat(4)27.51%
Revenue beat(8)2
Avg Revenue beat(8)-6.5%
Revenue beat(12)4
Avg Revenue beat(12)-1.08%
Revenue beat(16)8
Avg Revenue beat(16)11.63%
PT rev (1m)0%
PT rev (3m)0.61%
EPS NQ rev (1m)3.94%
EPS NQ rev (3m)2.09%
EPS NY rev (1m)13.78%
EPS NY rev (3m)16.45%
Revenue NQ rev (1m)-0.02%
Revenue NQ rev (3m)-2.23%
Revenue NY rev (1m)2.4%
Revenue NY rev (3m)4.61%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.21
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.45
EYN/A
EPS(NY)-1.31
Fwd EYN/A
FCF(TTM)-1.38
FCFYN/A
OCF(TTM)-1.37
OCFYN/A
SpS0.76
BVpS-2.4
TBVpS-2.4
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -54.98%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 92.75%
FCFM N/A
ROA(3y)-48.71%
ROA(5y)-46.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.51%
GM growth 5YN/A
F-Score2
Asset Turnover0.28
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 16.02%
Cap/Sales 0.79%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.46
Quick Ratio 4.16
Altman-Z -7.84
F-Score2
WACC5.44%
ROIC/WACCN/A
Cap/Depr(3y)74.54%
Cap/Depr(5y)119.38%
Cap/Sales(3y)2.31%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)47.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%35.71%
EPS Next Y22.36%
EPS Next 2Y9.77%
EPS Next 3Y12.37%
EPS Next 5YN/A
Revenue 1Y (TTM)-37.54%
Revenue growth 3Y27.85%
Revenue growth 5Y98.48%
Sales Q2Q%27.59%
Revenue Next Year6.59%
Revenue Next 2Y8.42%
Revenue Next 3Y25.43%
Revenue Next 5Y33.94%
EBIT growth 1Y54.35%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-21.15%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-14.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-15.63%
OCF growth 3YN/A
OCF growth 5YN/A